Aslan Pharmaceuticals Ltd ADR (ASLN)

1.560
-0.050(-3.11%)
After Hours
1.590
+0.030(+1.923%)
- Real-time Data
  • Volume:
    443,614
  • Bid/Ask:
    1.560/1.600
  • Day's Range:
    1.560 - 1.640

ASLN Overview

Prev. Close
1.61
Day's Range
1.56-1.64
Revenue
-
Open
1.64
52 wk Range
1.42-6.65
EPS
-0.44
Volume
443,614
Market Cap
108.6M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,026,757
P/E Ratio
-
Beta
2.45
1-Year Change
-23.9%
Shares Outstanding
69,617,212
Next Earnings Date
Nov 04, 2021
What is your sentiment on Aslan Pharmaceuticals Ltd ADR?
or
Market is currently closed. Voting is open during market hours.

Aslan Pharmaceuticals Ltd ADR News

Aslan Pharmaceuticals Ltd ADR Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Aslan Pharmaceuticals Ltd ADR Company Profile

Aslan Pharmaceuticals Ltd ADR Company Profile

Employees
18

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company’s clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Read More
  • any idea to hold or sale
    0
    • Hold
      0
  • why is down from 8 to 5.50?
    0
    • 10 my dear
      0
      • Why ?
        0
    • 9 Today
      0
      • ASLAN Pharmaceuticals (ASLN) , a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced positive interim unblinded data from the three dose cohorts of its ongoing randomised, double-blind placebo controlled multiple ascending dose study of ASLAN004 for the treatment of moderate to severe atopic dermatitis (AD). ASLAN004 was shown to be well tolerated across all doses and showed improvements compared to placebo in all efficacy endpoints, supporting its potential as a differentiated, novel treatment for AD.
        0
        • Great news!!!! 🥳🥳🥳
          0
          • All the way to FDA approval
            0
            • Its going to run here!
              0
              • SGBX or HTZ what do you guys think?
                0
                • htz
                  0
              • we had several .50 cent bumps 30 min ago. If this thing does bump back up it could go quick.
                0
                • In at $2.90 Good Luck Kofi
                  0
                  • Mick Westfor some reason it is showing me 100,000 only
                    0
                  • Kofi Kofi You to Kofi. I'm looking at HTZ or SGBX. Still waiting for a small pump to get out of this one.
                    0
                  • Jagdeep Singh currently 4.4 mil. It's got some power to move, but still bleeding. I'm holding on a little longer and watching HTZ and SGBX closely
                    0
                • I jump in at $2.86
                  0
                  • Kofi Kofi Smart man. Lets make back our ASLN losses hahahaha. This could go parabolic. Good Luck all day.
                    0
                  • Mick West Yeah. Hopefully, we get a green day.  I'm new to this and have a lot to learn. Good Luck.
                    0
                  • Mick West I don't know if I should sell before or after the market opens.
                    0
                • Watch out everyone.
                  0
                  • $4.00+ any day on good data
                    0
                    • Today is the Day.  Maybe will reach >5. Take care.
                      0
                  • Target is updated to strongly?
                    0
                    • Positive FDA!!
                      0
                      • Some thing going on
                        0
                        • Stock is making day high
                          0
                          • Some thing big is on its way
                            0
                            • Dont Sell!! hold or buy, upside off 243%, google it.
                              0
                              • Any thing is possible. Stay tight , do not sell , if breaks 9 look for $90
                                0
                                • Dont Sell!! hold or buy, upside to 243%, google it.
                                  0
                              • Or big pharma offered to buy aslan
                                0
                                • Aslan004 expedite review moving in phase 2and 3 for sure.
                                  0
                                  • positive FDA?
                                    0
                                    • yes!! go baby... we flight
                                      0
                                  • Now what? Hoping this stock recovers from the ADS issuance at$2.50
                                    0
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.